Status
Conditions
Treatments
About
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
Full description
Circulating plasma cells (CPCs) represents a phenotypic subset of bone marrow multiple myeloma (MM) cells, which would contribute to the progression and dissemination of the tumor. High-sensitivity techniques such as multiparameter flow cytometry provide a tool for better detection of CPCs; however, a clear threshold has not been identified. The primary objective of the current study is to identify an optimal threshold for CPCs quantified by 8-color flow cytometry (with antibodies to CD38, CD138, CD45, CD56, CD19, CD117 and cytoplasmic kappa and lambda immunoglobulin light chains) and determine the specific relationship between CPCs level and the prognosis of MM. In addition, the evaluation of CPCs at multiple time points will be performed to explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must meet all of the following inclusion criteria.
Exclusion criteria
Patients meeting any of the following exclusion criteria will not be included in the study.
458 participants in 1 patient group
Loading...
Central trial contact
Chunyan Sun
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal